Globally, people get animal protein mostly from chickens, with pigs and cattle in second and third place. A 2023 report ...

Emma Dimery joined the clinical trial after running out of treatment options. For two years, she's been cancer free.

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -24.41% and 83.48%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stoc ...

acceptphoto via Shutterstock Who’s up for some CRISPR-y bacon? This week, the Food and Drug Administration approved gene-edited pigs developed by PIC, a biotechnology company specializing in ...

Genomics company, Integrated DNA Technologies, is rewriting the future of genomics, pioneering new innovations in a bold move ...

From enabling functional cures for genetic diseases to revolutionizing agriculture and biotechnology, CRISPR is poised to reshape global industries. The next decade will witness deeper integration of ...

CRISPR Therapeutics stock is heavily shorted in the weeks going into earnings The short-sellers are betting against the name in a big way, with more than 20 million shares sold short as of the ...

CRISPR is not only established ... Many organizations are still using only open-source point solutions, online design tools, or even Excel for these purposes. This approach is not scalable ...

Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better ...

CRISPR Therapeutics won its first regulatory approval a little over a year ago, and has compelling candidates in the pipeline. Of course, Vertex's success didn't happen overnight -- and the ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $34.26, marking a -1.81% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.46%.